Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merck & Company (MRK), Allogene Therapeutics (ALLO) and Beta Bionics, Inc. (BBNX) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Merck & Company (MRK)
In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Merck & Company, with a price target of $150.00. The company’s shares closed last Tuesday at $112.56.
According to TipRanks.com, Bansal is a 5-star analyst with an average return of
Currently, the analyst consensus on Merck & Company is a Moderate Buy with an average price target of $134.55, representing a 15.5% upside. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $142.00 price target.
See the top stocks recommended by analysts >>
Allogene Therapeutics (ALLO)
Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics today and set a price target of $10.00. The company’s shares closed last Tuesday at $2.32.
According to TipRanks.com, Amin is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Allogene Therapeutics with a $8.71 average price target, a 259.9% upside from current levels. In a report issued on April 13, TD Cowen also maintained a Buy rating on the stock.
Beta Bionics, Inc. (BBNX)
Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Beta Bionics, Inc. today and set a price target of $20.00. The company’s shares closed last Tuesday at $12.27, close to its 52-week low of $11.43.
According to TipRanks.com, Block is a 4-star analyst with an average return of
Beta Bionics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $20.00, representing a 53.5% upside. In a report issued on April 15, Truist Financial also maintained a Buy rating on the stock with a $18.00 price target.
Read More on MRK:
Disclaimer & DisclosureReport an Issue
- Merck reports FDA approved Idvynso for treatment of HIV-1
- Merck setback has positives and negatives for Arcus Biosciences, says BofA
- Merck study miss not a read for Arcus, says H.C. Wainwright
- Merck and Eisai’s combination for RCC did not meet primary Phase 3 endpoints
- Merck announces FDA granted priority review for supplemental sBLAs for Keytruda
